Simulations Plus

Simulations Plus announced today that it received an extension to its funded research collaboration with the FDA to develop the GastroPlus OCAT model.

Simulations Plus subsidiary DILIsym was awarded a Fast-Track SBIR grant to fund the development of software for predicting drug-induced kidney injury.

Enhancements to mechanistic dermal absorption model in GastroPlus™ will target non-pharmaceutical markets

Record quarter as revenues grow 26.7%, 9MoFY18 net income up 63.8%
Board of Directors Announces Quarterly Dividend of $0.06 Per Share

Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its third quarter financial results for fiscal year 2018, the period ended May 31, 2018, after the close of the financial markets on Tuesday, July 10, 2018.

Improvements to AI technology and extensions to HTPK Simulation Module further support discovery research efforts

Executive with relevant expertise in multiple industries succeeds retiring CEO Walt Woltosz, who remains chairman of the board

Significant improvements support internal research activities through regulatory interactions

US FDA Continues Its Goal of Propelling Model-Based Drug Development Forward

Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced that it will be distributing a one-time $1,000 discretionary cash bonus to each of its employees.

Simulations Plus, Inc. (NASDAQ: SLP) will be discussing their earnings results in their Q2 Earnings Call to be held on April 9, 2018, at 4:15 PM Eastern Time.

Board of Directors Announces Quarterly Dividend of $0.06 Per Share

FinancialBuzz.com News Commentary

Major update to preclinical and clinical trial data analysis software addresses user requests